SV2 PET Imaging With [11C]APP311

ConditionsSchizophrenia and Other Psychotic Disorders Cannabis Use Disorder Healthy

Trial statusActive, not recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-85

SponsorYale University

About this trial

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Willing and able to give voluntary written informed consent

Male and Female subjects, age 18 to 65 years, inclusive

Disqualifiers

MRI metal exclusions and claustrophobia.

Education completed is less than 12 years

Trial population

Recruiting Subjects with Schizophrenia and other Psychotic disorders Cannabis Use Disorder Healthy controls

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

[11C]APP311
Drug
It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

Treatment groups

250 Participants

are divided into 3 treatment groups

Group A: Schizophrenia and other psychotic disorders1 intervention

Group B: Cannabis Use Disorder1 intervention

Group C: Healthy Control1 intervention

Trial outcomes

Primary outcomes

Synaptic density in psychiatric disorders using SV2A receptor PET Imaging with [11C]APP311

To compare synaptic vesicle protein 2A (SV2A) density in two groups of subjects with psychiatric disorders (namely 'schizophrenia and other psychotic disorders', and 'cannabis use disorder') to that in healthy controls using the PET radiotracer 11C-APP311

Time frame

One test day (one time point).

Secondary outcomes

Correlation of Synaptic density with cognition and EEG

To correlate SV2A density with concurrent measures of information processing such as cognitive performance on a neuropsychiatric battery and electroencephalographic (EEG) measures

Time frame

One test day (one time point).

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yale University

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: